Report notes lack of CMS coverage for CBD oils and limited commercial insurance reimbursement

Report notes lack of CMS coverage for CBD oils and limited commercial insurance reimbursement The passage provides general industry observations about Medicare/Medicaid and commercial insurers' stance on CBD products. It contains no specific names, transactions, dates, or actionable leads linking powerful actors to misconduct. The information is largely already public and offers minimal investigative value. Key insights: CMS and state Medicaid programs currently do not cover CBD oils.; Coverage could change if states add CBD to their Medicaid plans, possibly requiring CMS approval.; Commercial insurers generally exclude CBD oils because they are not FDA‑approved, except for Epidiolex.